<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115918</url>
  </required_header>
  <id_info>
    <org_study_id>922733</org_study_id>
    <nct_id>NCT03115918</nct_id>
  </id_info>
  <brief_title>Pancreatic Duct Stent for Acute Necrotizing Pancreatitis</brief_title>
  <official_title>Randomized Trial Examining the Impact of Pancreatic Duct Stent Placement in Patients With Acute Necrotizing Pancreatitis in the Prevention of Walled-off Necrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research design is a randomized prospective clinical study comparing the incidence of
      Walled Off Necrosis (WON) in patients with acute necrotizing pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized trial comparing the incidence of WON in patients with acute necrotizing
      pancreatitis, according to the placement or non-placement of an Advanix or a Cook Pancreatic
      Duct (PD) stent during Endoscopic Retrograde Cholangiopancreatography (ERCP) within 1-2 week
      of symptom onset. Patients will be randomly allocated to either treatment arm i.e. to either
      PD stent placement or no PD placement in a 1:1 ratio. The type of stent to be placed is at
      the discretion of the physician based on the clinical needs and presentation of the patient
      at the time of procedure. This is based on factors such as the size of the WON, the patient's
      anatomy, and other variables. Patients will be assessed at 4-6 weeks post-ERCP for the
      primary outcome measure, which is the incidence of WON on contrast-enhanced CT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of WON between the PD stent and no PD stent groups</measure>
    <time_frame>4-6 weeks post-index ERCP</time_frame>
    <description>The primary aim of the study is to compare the incidence of WON between the PD stent and no PD stent groups at 4-6 weeks post-index ERCP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of WON Intervention</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of WON requiring intervention of any type (including endoscopic, surgical or interventional radiology interventions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of DPDS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of DPDS, as determined by ERCP or Magnetic Resonance Cholangiopancreatography (MRCP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of additional interventions resulting from complications</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of other interventions undertaken as clinically indicated for complications of acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Acute pancreatitis</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical adverse events related to underlying acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Local complications</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical adverse events arising as a result of local complications of acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Systemic complications</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical adverse events arising as a result of systemic complications of acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>6 weeks</time_frame>
    <description>Duration of hospitalization in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost</measure>
    <time_frame>6 weeks</time_frame>
    <description>Total hospital costs in US Dollars</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Necrotizing Pancreatitis</condition>
  <condition>Walled Off Necrosis</condition>
  <arm_group>
    <arm_group_label>Pancreatic Duct Stent Placement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Pancreatic Duct Stent Placement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will not have a pancreatic Duct stent placed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pancreatic Duct Stent Placement</intervention_name>
    <description>Patients will be randomly allocated to either treatment arm to have a PD stent placed.</description>
    <arm_group_label>Pancreatic Duct Stent Placement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Pancreatic Duct Stent Placement</intervention_name>
    <description>Patients will be randomly allocated to either treatment arm and not receive PD placement.</description>
    <arm_group_label>No Pancreatic Duct Stent Placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 19 years

          2. The subject (or when applicable the subject's LAR) is capable of understanding and
             complying with protocol requirements.

          3. The subject (or when applicable the subject's LAR) is able to understand and willing
             to sign an informed consent form prior to the initiation of any study procedures.

          4. All patients with acute necrotizing pancreatitis and bedside index for severity in
             acute pancreatitis (BISAP) score of ≥ 3, who have been referred to Florida Hospital
             for Percutaneous endoscopy gastrojeunostomy (PEG-J) tube placement and/or ERCP for
             assessment of the PD

          5. Absence of pancreatic fluid collection (defined as those &gt; 3cm in size located along
             the course of the main PD on cross-sectional imaging) at the time of study enrollment

          6. No disconnected pancreatic duct syndrome (DPDS) on cross-sectional imaging or ERCP

        Exclusion Criteria:

          1. Age &lt;19 years

          2. Unable to obtain consent for the procedure from either the patient or LAR

          3. Patients with acute interstitial pancreatitis, without pancreatic necrosis

          4. Patients with BISAP score ≤ 2

          5. Patients with pancreatic fluid collection &gt; 3cm in size located along the course of
             the main PD on cross-sectional imaging prior to the initial ERCP

          6. Patients with DPDS on cross-sectional imaging or ERCP

          7. Unable to safely undergo ERCP for any reason

          8. Failed cannulation during ERCP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Varadarajulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyam Varadarajulu, MD</last_name>
    <phone>407.303.2750</phone>
    <email>Shyam.Varadarajulu.MD@flhosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Barron-Nelson, RN, MSN</last_name>
    <phone>407.303.5503</phone>
    <email>Robin.Barron@flhosp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Interventional Endoscopy - Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyam Varadarajulu, MD</last_name>
      <phone>407-303-2750</phone>
      <email>Shyam.Varadarajulu.MD@flhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Robin E Barron-Nelson, RN, MSN</last_name>
      <phone>407.303.5503</phone>
      <email>Robin.Barron@flhosp.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013 Jun;144(6):1252-61. doi: 10.1053/j.gastro.2013.01.068. Review.</citation>
    <PMID>23622135</PMID>
  </reference>
  <reference>
    <citation>Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012 Nov;143(5):1179-87.e1-3. doi: 10.1053/j.gastro.2012.08.002. Epub 2012 Aug 8.</citation>
    <PMID>22885331</PMID>
  </reference>
  <reference>
    <citation>Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.</citation>
    <PMID>23100216</PMID>
  </reference>
  <reference>
    <citation>Freeman ML, Werner J, van Santvoort HC, Baron TH, Besselink MG, Windsor JA, Horvath KD, vanSonnenberg E, Bollen TL, Vege SS; International Multidisciplinary Panel of Speakers and Moderators. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas. 2012 Nov;41(8):1176-94. doi: 10.1097/MPA.0b013e318269c660.</citation>
    <PMID>23086243</PMID>
  </reference>
  <reference>
    <citation>Garg PK, Madan K, Pande GK, Khanna S, Sathyanarayan G, Bohidar NP, Tandon RK. Association of extent and infection of pancreatic necrosis with organ failure and death in acute necrotizing pancreatitis. Clin Gastroenterol Hepatol. 2005 Feb;3(2):159-66.</citation>
    <PMID>15704050</PMID>
  </reference>
  <reference>
    <citation>Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. doi: 10.1016/j.pan.2013.07.063.</citation>
    <PMID>24054878</PMID>
  </reference>
  <reference>
    <citation>Nadkarni NA, Kotwal V, Sarr MG, Swaroop Vege S. Disconnected Pancreatic Duct Syndrome: Endoscopic Stent or Surgeon's Knife? Pancreas. 2015 Jan;44(1):16-22. doi: 10.1097/MPA.0000000000000216. Review.</citation>
    <PMID>25493375</PMID>
  </reference>
  <reference>
    <citation>van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, van Ramshorst B, Nieuwenhuijs VB, Timmer R, Laméris JS, Kruyt PM, Manusama ER, van der Harst E, van der Schelling GP, Karsten T, Hesselink EJ, van Laarhoven CJ, Rosman C, Bosscha K, de Wit RJ, Houdijk AP, van Leeuwen MS, Buskens E, Gooszen HG; Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010 Apr 22;362(16):1491-502. doi: 10.1056/NEJMoa0908821.</citation>
    <PMID>20410514</PMID>
  </reference>
  <reference>
    <citation>Casas M, Mora J, Fort E, Aracil C, Busquets D, Galter S, Jáuregui CE, Ayala E, Cardona D, Gich I, Farré A. [Total enteral nutrition vs. total parenteral nutrition in patients with severe acute pancreatitis]. Rev Esp Enferm Dig. 2007 May;99(5):264-9. Spanish.</citation>
    <PMID>17650935</PMID>
  </reference>
  <reference>
    <citation>Gupta R, Patel K, Calder PC, Yaqoob P, Primrose JN, Johnson CD. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II &gt; or =6). Pancreatology. 2003;3(5):406-13. Epub 2003 Sep 24.</citation>
    <PMID>14526151</PMID>
  </reference>
  <reference>
    <citation>Louie BE, Noseworthy T, Hailey D, Gramlich LM, Jacobs P, Warnock GL. 2004 MacLean-Mueller prize enteral or parenteral nutrition for severe pancreatitis: a randomized controlled trial and health technology assessment. Can J Surg. 2005 Aug;48(4):298-306.</citation>
    <PMID>16149365</PMID>
  </reference>
  <reference>
    <citation>Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. Dig Surg. 2006;23(5-6):336-44; discussion 344-5. Epub 2006 Dec 12.</citation>
    <PMID>17164546</PMID>
  </reference>
  <reference>
    <citation>Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218. Epub 2013 Jul 30. Erratum in: Am J Gastroenterol. 2014 Feb;109(2):302.</citation>
    <PMID>23896955</PMID>
  </reference>
  <reference>
    <citation>Yi F, Ge L, Zhao J, Lei Y, Zhou F, Chen Z, Zhu Y, Xia B. Meta-analysis: total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. Intern Med. 2012;51(6):523-30. Epub 2012 Mar 15.</citation>
    <PMID>22449657</PMID>
  </reference>
  <reference>
    <citation>Varadarajulu S, Noone T, Hawes RH, Cotton PB. Pancreatic duct stent insertion for functional smoldering pancreatitis. Gastrointest Endosc. 2003 Sep;58(3):438-41.</citation>
    <PMID>14528225</PMID>
  </reference>
  <reference>
    <citation>Lau ST, Simchuk EJ, Kozarek RA, Traverso LW. A pancreatic ductal leak should be sought to direct treatment in patients with acute pancreatitis. Am J Surg. 2001 May;181(5):411-5.</citation>
    <PMID>11448431</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027.</citation>
    <PMID>20189503</PMID>
  </reference>
  <reference>
    <citation>Varadarajulu S, Rana SS, Bhasin DK. Endoscopic therapy for pancreatic duct leaks and disruptions. Gastrointest Endosc Clin N Am. 2013 Oct;23(4):863-92. doi: 10.1016/j.giec.2013.06.008. Epub 2013 Jul 12. Review.</citation>
    <PMID>24079795</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Pancreatitis, Acute Necrotizing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

